Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Feasibility of Ethanolization of Vein of Marshall With Specific Catheter in Atrial Fibrillation Ablation

NCT05427435 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-05-09
Last updated
2025-06-17

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

Marshall ethanolisation

Marshall ethanolisation: Destruction of Marshall bundles by ethanol 96% infusion (3 separate injections of 3.3ml)

Study summary

In patients with persistent AF (PsAF), ablation limited to pulmonary vein (PV) isolation is the most straightforward approach, but results only in 50% of arrhythmia freedom at 1 year follow-up. Substrate modification strategies have failed to demonstrate their superiority with variable reported success rate. The Marshall network is a highly arrhythmogenic structure that has not been systematically targeted so far, probably because of the absence of dedicated tools to make its ablation simple and easy. We sought to investigate the use of a specific catheter for visualization and ethanolization of vein of Marshall allowing to systematically include this target in the ablation set.

The main objective of this study is to demonstrate the feasibility to use the Targeted Endovascular Delivery (TED) catheter specifically for visualization and ethanolization of vein of Marshall.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Suitable candidate for catheter ablation of atrial fibrillation defined as: * history of symptomatic persistent atrial fibrillation * Redo procedure for persistent AF or paroxysmal AF with isolated PV and no history of ethanol infusion in the VOM. * Age \> 18 years of both genders * Patient affiliated or beneficiary of social security scheme * Free, informed and written consent signed by the participant and the principal investigator (at least at the inclusion date and before all exams required for the clinical research) * Effective contraception for women of childbearing potential Exclusion Criteria: * Minor * Documented left atrial thrombus or another abnormality which precludes catheter introduction * Contraindication to anticoagulation therapy (heparin, warfarin, or novel oral anticoagulant \[NOAC\] * Contraindication to iodinated contrast product XENETIX® (iobitridol hypersensivity or at one of these excipients, history of major immediate reaction or cutaneous reaction to XENETIX® infusion, thyrotoxicosis) * Hypersensitivity to ethanol * Unstable angina or ongoing myocardial ischemia * Myocardial infarction within 3 months prior to inclusion * Congenital heart disease, where the underlying abnormality increases the ablation risk * Severe bleeding, clotting or thrombotic disorder * Pregnant, parturient or nursing women * Unable or unwilling to provide written informed consent * Patient detained by judicial or administrative order * Patient under psychiatric care * Patient admitted in a social or healthcare establishment for any purpose other than the research * Subject to a legal protection order (guardianship, patient under legal protection)

Primary outcome measure(s)

  • Acute success rate of the procedure — 12 months
    Success rate complete realization of ethanolization procedure

Trial sites (1)

FacilityCityRegionStatus
CHU de Bordeaux Pessac France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05427435 on ClinicalTrials.gov ↗ ← All trials in France